BioWorld Asia

Dec. 15, 2004

MediGene's Phase III Drug Effective In Genital Warts

MUNICH, Germany - MediGene AG completed its second Phase III trial of Polyphenon E, a treatment for genital warts, getting significant clinical effects compared to placebo, as well as good tolerability. (BioWorld International) Read More

Chroma Raises £5M More To Add To Second Round

New Antibiotic Class Might Thrash Drug-Resistant TB

European Report: New Biotech Products Should Rise In Future

Pepscan Enters Vaccine Deal Aimed At Cytokine With Cytos

ExonHit Hits First Milestone In Partnership With Allergan

Cresset Using FieldScreen As Drug Discovery Platform

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 29, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...